公开(公告)号：US20240115724A1

公开(公告)日：2024-04-11

申请号：US18320869

申请日：2023-05-19

Applicant: AbbVie Inc.

Inventor： Shweta SINGH ,  Jennifer Hope RICHARDSON ,  Laura Patterson SERWER ,  Jonathan Alexander TERRETT ,  Susan E. MORGAN-LAPPE ,  Tracy HENRIQUES ,  Sherry L. RALSTON ,  Marvin Robert LEANNA ,  Ilaria BADAGNANI

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K47/6849 ,  A61K47/6817 ,  A61K47/6851 ,  A61K47/6889 ,  A61P35/00 ,  C07K16/2881 ,  C07K2317/33 ,  C07K2317/77 ,  C07K2319/50

Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

公开(公告)号：US20190111150A1

公开(公告)日：2019-04-18

申请号：US16159559

申请日：2018-10-12

Applicant: AbbVie Inc.

Inventor： Shweta SINGH ,  Jennifer Hope RICHARDSON ,  Laura Patterson SERWER ,  Jonathan Alexander TERRETT ,  Susan E. MORGAN-LAPPE ,  Tracy HENRIQUES ,  Sherry L. RALSTON ,  Marvin Robert LEANNA ,  Ilaria BADAGNANI ,  Sahana BOSE

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/28

Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

公开(公告)号：US20160031986A1

公开(公告)日：2016-02-04

申请号：US14798849

申请日：2015-07-14

Applicant: AbbVie Inc.

Inventor： Ming-Jiu CHEN ,  Chung-Ming HSIEH ,  Jijie GU ,  Susan E. MORGAN-LAPPE ,  Yingchun LI

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.

Abstract translation: 本文描述了DLL4结合蛋白，包括抗体，CDR-移植抗体，人源化抗体及其DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4和/或VEGF活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成。